In vitro and in vivo properties of bicyclic lactam inhibitors: A novel class of low molecular weight peptidomimetic thrombin inhibitors

Thrombosis Research

Volumn 100, Issue 3, 2000, Pages 195-209

  Leblond, L ^a   Grouix, B ^a   Boudreau, C ^a   Yang, Q ^a   Siddiqui, M A ^a   Winocour, P D ^a  

^a Shire Canada   (Canada)

Author keywords

Antithrombotic agent; Bicyclic lactam inhibitor; Peptidomimetic; Thrombin inhibitor

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; BICYCLIC LACTAM INHIBITOR; BLOOD CLOTTING FACTOR 10A; ECARIN; LACTAM; PLASMIN; THROMBIN INHIBITOR; TRYPSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING TIME; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG POTENCY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RAT; THROMBIN TIME; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENESIS; VEIN THROMBOSIS;

ANIMALS; ANTICOAGULANTS; BICYCLO COMPOUNDS, HETEROCYCLIC; BLOOD COAGULATION; CAROTID ARTERY THROMBOSIS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KINETICS; LACTAMS; MALE; MOLECULAR MIMICRY; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; PARTIAL THROMBOPLASTIN TIME; PLATELET AGGREGATION; RATS; RATS, SPRAGUE-DAWLEY; SERINE PROTEINASE INHIBITORS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN; THROMBOSIS; VENOUS THROMBOSIS;

EID: 0034324766     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00333-9     Document Type: Article

References (57)

1. The coagulation cascade: Initiation, maintenance, and regulation
2. Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets
3. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation
4. Initiation of coagulation and relationships between intrinsic and extrinsic coagulation pathways
5. Understanding thrombin and haemostasis
6. New anticoagulant strategies
7. New anticoagulant strategies. Current status and future potential
8. Currents trends in the development of anticoagulant and antithrombotic drugs
9. Direct thrombin inhibitors in cardiovascular medicine
10. Clinical applications of new antithrombotic agents
11. Clinical status of direct thrombin inhibitors
12. Leeches to hirulogs and other thrombin-directed antithrombotics
13. The development of hirudin as an antithrombotic drug
14. Hirudin: Clinical potential of a thrombin inhibitor
15. Recombinant hirudin (Lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study
16. The ideal anti-thrombotic drug
17. Synthetic low-molecular weight thrombin inhibitors: Molecular design and pharmacological profile
18. Thrombin inhibitor design
19. Small, noncovalent serine protease inhibitors
20. Thrombin inhibitors as antithrombotic agents: The importance of rapid inhibition
21. Design, synthesis, and evolution of a novel, selective, and orally bioavailable class of thrombin inhibitors: P1-arginal derivatives incorporating P3-P4 lactam sulfonamide moieties
22. Antithrombotic activity in vivo of SDZ 217-766, a low-molecular weight thrombin inhibitor in comparison to heparin
23. Progress towards the discovery of orally active thrombin inhibitors
24. Challenges in the development of orally bioavailable thrombin active site inhibitors
25. Pharmacologic aspects of the development of selective thrombin inhibitors as anticoagulants
26. Rational design of boropeptide thrombin inhibitors: β,β-Dialkyl-phenethylglycine P2 analogs of DUP 714 with greater selectivity over complement factor I and an improved safety profile
27. Potent bicyclic lactam inhibitors of thrombin: Part I: P3 modifications
28. Potent and selective bicyclic lactam inhibitors of thrombin: Part 2: P1 modifications
29. Potent and selective bicyclic lactam inhibitors of thrombin: Part 3: P1' modifications
30. Bifunctional thrombin inhibitors based on the sequence of hirudin 45-65
31. Enzyme kinetics
32. The behavior and significance of slow-binding enzyme inhibitors
33. Preparation of suspensions of washed platelets from humans
34. Continued platelet interaction with de-endothelialized aortae associated with slower re-endothelialization and more extensive intimal hyperplasia in spontaneously diabetic BB Wistar rats
35. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: Comparison with heparin and recombinant hirudin
36. A precise and rapid microtitre plate lysis assay: Methodology, kinetic modeling and measurement of catalytic constants for plasminogen activation during fibrinolysis
37. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes
38. Rat model of arterial thrombosis induced by ferric chloride
39. Venous thrombosis and the 'Wessler Test'
40. Analysis of thrombin generation in plasma
41. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis - Comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban
42. In vitro and in vivo characterization of a neutral boron-containing thrombin inhibitor
43. α-Hydroxy- and α-ketoester functionalized thrombin inhibitors
44. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis
45. Thrombin inhibitors suppress the thrombin-throbomodulin-mediated generation of activated protein C
46. The protein C anticoagulant pathway
47. Antithrombin agents as anticoagulants and antithrombotics: Implications in drug development
48. Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin
49. Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma
50. The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma of extrinsec and intrinsec activation
51. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor
52. In vitro effects of inogatran, a selective low molecular weight thrombin inhibitor
53. Ecarin clotting time: A predictive coagulation assay for the antithrombotic activity of argatroban in the rat
54. Antithrombotic actions of argatroban in rat models of venous mixed and arterial thrombosis, and its effects on the tail transection bleeding time
55. Effect of a novel thrombin active-site inhibitor on arterial and venous thrombosis
56. Experimental studies on the antithrombotic action of a highly effective synthetic thrombin inhibitor
57. Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time